Surrey Heartlands

Joint Formulary & PAD

Finerenone - Heart failure

You are here : Home > Formulary Search > Finerenone - Heart failure

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Green (see narrative)
Formulations :
  • Tablets
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
Guidelines
NICE
SPC
Restrictions / Comments :
Important

For adults with symptomatic chronic heart failure and left ventricular ejection fraction (LVEF) less than, or equal to 40%

Documents :
 
NICE Technology Appraisal
NICE TA1182: Finerenone for treating chronic heart failure with preserved or mildly reduced ejection fraction
Information
Finerenone NICE TA local implementation paper - Oct 26

Documentation

  • No records returned.

PAD Profile

ChemicalSubstance :
Finerenone
Indication :
Heart failure
Group Name :
Keywords :
chronic heart failure, HF, LVEF
Brand Names Include :
Kerendia
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Heart failure
Supporting Documents :
2

Committee Recommendations (1)

06 Oct 26 - Surrey & Sussex Area Prescribing Committee (APC)

The APC approved the use of finerenone with a GREEN formulary status, for adults with symptomatic chronic heart failure and left ventricular ejection fraction (LVEF) ≥40%, in accordance with NICE TA1182 recommendation.

An application to change the formulary status of eplerenone, for its licensed indication, from BLUE to GREEN was also approved for Surrey, aligning it with the Sussex existing position.

Other Indications

Below are listed other indications that Finerenone is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Heart failure.